Литература
1. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR et al. Randomized Controlled Trial Testing the Effects of Weight Loss
on Nonalcoholic Steatohepatitis (NASH) . Hepatology. 2010; 51: 121-129. doi: 10.1002/hep.23276.
2. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR et al. Randomized Controlled Trial Testing the Effects of Weight Loss
on Nonalcoholic Steatohepatitis (NASH). Hepatology. 2010; 51: 121-129. doi: 10.1002/hep.23276.
3. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015; 149: 367–378. doi: 10.1053/j.gastro.2015.04.005.
4. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology. 2016, 64; 13: 88-402. doi: 10.1016/j.jhep.2015.11.004.
5. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline from the American Association for the Study of Liver Diseases. Hepatology. 2017; 7(11). 1-88. doi: 10.1002/hep.25762.
6. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362(18):1675–1685. doi: 10.1056/NEJMoa0907929.
7. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005; 142: 37-46.
8. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306:1549-1556. doi: 10.1001/jama.2011.1437.
9. Schürks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ. 2010; 341: с5702. doi: 10.1136/bmj.c5702.
10. Ивашкин В.Т. Ядерные рецепторы и патология печени. Часть 1-я. РЖГГК. 2010; 3: 4-8.
11. Arab JP, Karpen SJ, Dawson PA. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology. 2017; 65: 350-362.
12. Lefebvre E, Moyle G, Reshef R, Richman LP, Thompson M, Hong F et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS ONE. 2016; 11: e0158156. doi: 10.1371/journal.pone.0158156.
13. Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018; 67(5):1754-1767. doi:10.1002/hep.29477.
14. Ratziu V, Harrison SA, Francque S, Pierre Bedossa P, Lehert P, Serfaty L et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016; 150: 1147-1159.e5. doi: 10.1053/j.gastro.2016.01.038.
15. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebocontrolled trial. Lancet. 2015; 385: 956-965. doi: 10.1016/S0140-6736(14)61933-4.
16. Hayakawa R, Hayakawa T, Takeda K, Ichijo H. Therapeutic targets in the ASK1-dependent stress signaling pathways. Proc Jpn Acad Ser B Phys Biol Sci. 2012; 88: 434-453.
17. Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017; 66: 180-190.
18. Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology 2018; 67: 549-559.
19. Kuntz E, Kuntz HD, editors. Hepatology. Heidelberg: Springer; 2008: p. 894–896.
20. Gundermann KJ, Kuenker A, Kuntz E, Drozdzik M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep. 2011; 63(3):643–659.
21. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., Тихонов И.Н., Широкова Е.Н., Буеверов А.О. и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. РЖГГК. 2016; 2: 24-42.
22. Li JH, Chen XY, Zhong CF, Min J. A randomized controlled study of essential phospholipids (Essentiale capsules) in the treatment of fatty liver. Infect Dis Info. 2000;13(4):180–181.
23. Gonciarz Z, Besser P, Lelek E, Gundermann KJ, Johannes KJ. Randomised placebo-controlled double blind trial on “essential” phospholipids in the treatment of fatty liver associated with diabetes. Méd Chir Dig. 1988; 17(1): 61–65.
24. Sas E, Grinevich V, Efimov O, Shcherbina N. Beneficial influence of polyunsaturated phosphatidylcholine enhances functional liver condition and liver structure in patients with nonalcoholic steatohepatitis accom¬panied by diabetes type 2. Results of prolonged randomized blinded prospective clinical study. J Hepatol. 2013; 58: S549.
25. Бакулин И.Г., Сандлер Ю.Г. Гиполипидемическая терапия и печень. Российские Медицинские Вести. 2012; 17(1):43-51.
26. Драпкина . О.М., Зятенкова Е.В., Корнеева О.Н. Влияние полиненасыщенных фосфолипидов на показатели микроциркуляции, функцию эндотелия сосудов и липидный спектр у пациентов с артериальной гипертензией высокого риска и дислипидемией . Российские Медицинские Вести. 2013; 18(1):47-55.
27. Балукова Е.В., Успенский Ю.П.. Плейотропные эффекты эссенциальных фосфолипидов у больных с метаболическим синдромом. Consilium medicum, гастроэнтерология. 2011; 2: 12-16.
28. Мязин Р.Г. Неалкогольная болезнь печени: новые возможности терапии. Медицинский совет. 2014; 13: 18-20.
29. Минушкин О.Н., Масловский Л.В. Лечение жировой болезни печени различной этиологии: современные рекомендации. Эффективная фармакотерапия. 2013; 41(4):38-46.